Dengue, Cyclospora, measles, Ebola and new drug approvals test public-health defenses
Today’s health news centers on a dengue family cluster in Taiwan, expanding U.S. foodborne and measles outbreaks, diverging Ebola signals in Uganda and Congo, new FDA approvals for dermatomyositis and pancreatic cancer, and a medical-device cybersecurity disruption.
Taiwan reports a local dengue family cluster in Kaohsiung
Taiwan CDC reported three new local dengue cases in Gangshan District, Kaohsiung, all in the same household and all positive for dengue virus serotype 2. The index patient, a man in his 60s, developed fever, muscle and joint pain, and nausea on August 26; two household contacts were later confirmed and all three were hospitalized. Taiwan has recorded 145 confirmed dengue cases this year, including 10 local cases all in Kaohsiung and 135 imported cases, with Vietnam, Indonesia, and the Maldives the leading exposure locations. Heavy rain and warm weather raise mosquito density risk, so the immediate public-health focus is source reduction, NS1 rapid testing, TOCC history taking, and early reporting.
Read the full storyCyclospora lettuce outbreak expands to 20 U.S. states
U.S. officials expanded the multistate Cyclospora outbreak linked to recalled iceberg lettuce to 20 states after identifying cases in Georgia, Tennessee, and Texas. CDC’s August 27 update lists 11,458 cases, 495 hospitalizations, and two deaths; investigators continue to focus on iceberg lettuce grown at a central Mexico farm operated by Taylor Farms de Mexico. The recalled lettuce’s best-by dates have passed and the FDA says it remains confident the implicated product is off the market, but the outbreak still matters clinically because Cyclospora can cause prolonged watery diarrhea, fatigue, and appetite loss, and routine stool tests do not always screen for the parasite.
Read the full storyMeasles deaths underline the U.S. vaccination gap
Pennsylvania reported two deaths among unvaccinated Lancaster County residents who had measles, the first U.S. measles-related deaths of 2026. CDC’s latest national page shows 2,777 confirmed U.S. cases as of August 20, 36 outbreaks this year, and 94% of cases linked to outbreaks. The broader concern is immunity erosion: national MMR coverage among U.S. kindergarteners fell from 95.2% in 2019–2020 to 92.4% in 2025–2026, leaving about 280,000 kindergarteners at risk. With the United States facing its worst measles year since 1991, detection, isolation, contact tracing, and catch-up vaccination remain the practical response.
Read the full story
Uganda ends Ebola outbreak while Congo’s epidemic grows
WHO and Africa CDC welcomed the end of Uganda’s Bundibugyo Ebola outbreak after 42 consecutive days without a new confirmed case, following discharge of the last imported patient on July 16. Uganda reported 20 confirmed cases, including 15 imported from the Democratic Republic of the Congo and five local cases, with 18 recoveries and two deaths. The regional risk has not ended: WHO’s Africa office said the DRC outbreak had crossed 100 days and more than 5,200 cases, with transmission outpacing control efforts, Ituri accounting for about 85% of cases, and around 60% of recent weekly deaths occurring in the community rather than treatment centers. The contrast shows why cross-border surveillance, laboratories, treatment beds, safe burials, and community trust remain central.
Read the full storyFDA approvals add oral dermatomyositis therapy and targeted pancreatic-cancer treatment
The FDA approved Lisraya, or brepocitinib, as the first oral treatment specifically indicated for adults with dermatomyositis, a rare autoimmune disease affecting muscle and skin. In a 241-person phase 3 trial, the approved 30 mg once-daily dose improved the Total Improvement Score at week 52 versus placebo and helped physical function, skin disease activity, and corticosteroid reduction, but the drug carries boxed warnings for serious infections, malignancy, cardiovascular events, thrombosis, and increased all-cause mortality. Earlier this week, FDA also approved Rasonque, or daraxonrasib, for previously treated metastatic pancreatic adenocarcinoma; a 500-person trial showed median overall survival of 13.2 months versus 6.7 months with standard chemotherapy, making RAS-targeted treatment a notable option in a cancer usually detected late and hard to treat.
Read the full story
Boston Scientific cyber incident reaches manufacturing, orders, and new monitoring activations
Boston Scientific’s August 27 stakeholder update said a cybersecurity incident continues to affect certain IT systems, keeping the company in a network outage that disrupts operations. The company said affected systems include manufacturing, order processing, and customer shipments; customers may still submit orders electronically, but fulfillment is queued until systems are restored. Its investigation to date found no impact on existing implantable cardiac rhythm-management device function or previously enrolled remote monitoring, but new remote-monitoring activations for some cardiac devices are disrupted. The incident has become a medical-supply resilience issue, not just an enterprise IT event, because device logistics and patient monitoring workflows can affect clinical continuity even without confirmed device malfunction.
Read the full story
TPulled the most relevant stories from the last 24h — headlines, key points and original sources are all in.
JGot it. Wrote it up in four languages across six sections, leading with why this matters right now.
WFact-checked. Asked Jasper to tighten two figures and drop the AI-speak; the rest holds — ship it.
Explore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNewsExplore the world's news with MokiNews